- Home
- ENTA vs DBL Comparison
ENTA vs DBL Comparison
Compare ENTA & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- DBL
- Stock Information
- Founded
- ENTA 1995
- DBL 2011
- Country
- ENTA United States
- DBL United States
- Employees
- ENTA N/A
- DBL N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- DBL
- Sector
- ENTA Health Care
- DBL
- Exchange
- ENTA Nasdaq
- DBL Nasdaq
- Market Cap
- ENTA 316.2M
- DBL 292.0M
- IPO Year
- ENTA 2013
- DBL N/A
- Fundamental
- Price
- ENTA $12.65
- DBL $15.23
- Analyst Decision
- ENTA Strong Buy
- DBL
- Analyst Count
- ENTA 6
- DBL 0
- Target Price
- ENTA $20.33
- DBL N/A
- AVG Volume (30 Days)
- ENTA 387.8K
- DBL 61.0K
- Earning Date
- ENTA 11-17-2025
- DBL 01-01-0001
- Dividend Yield
- ENTA N/A
- DBL 8.67%
- EPS Growth
- ENTA N/A
- DBL N/A
- EPS
- ENTA N/A
- DBL N/A
- Revenue
- ENTA $65,324,000.00
- DBL N/A
- Revenue This Year
- ENTA $2.13
- DBL N/A
- Revenue Next Year
- ENTA $2.74
- DBL N/A
- P/E Ratio
- ENTA N/A
- DBL N/A
- Revenue Growth
- ENTA N/A
- DBL N/A
- 52 Week Low
- ENTA $4.09
- DBL $13.75
- 52 Week High
- ENTA $15.34
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- ENTA 66.08
- DBL 40.84
- Support Level
- ENTA $11.89
- DBL $15.14
- Resistance Level
- ENTA $13.00
- DBL $15.57
- Average True Range (ATR)
- ENTA 0.83
- DBL 0.13
- MACD
- ENTA 0.09
- DBL -0.02
- Stochastic Oscillator
- ENTA 80.78
- DBL 27.91
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.